We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Tirzepatideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Tirzepatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2025 with a typical study size of 1,437 participants.
Based on 12 studies · 2 meta-analyses · 10 RCTs · 69,784 total participants
Confidence
HighBy outcome
Tirzepatide has an evidence score of 7.8/10 — strong evidence based on 12 indexed studies, including 2 meta-analyses. An FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription. Representative study: PMID 38613667.
The commonly studied dose of Tirzepatide is Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tirzepatide (GIP/GLP-1 receptor agonist)
An FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
An FDA-approved drug, not a supplement: large phase-3 RCTs (SURPASS, SURMOUNT) and meta-analyses show strong, head-to-head-superior glycemic and weight-loss efficacy, tempered by real prescription-only risks.
Tirzepatide is a once-weekly subcutaneous peptide that activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
This dual mechanism enhances glucose-dependent insulin secretion, improves insulin sensitivity, slows gastric emptying, and powerfully suppresses appetite.
It is an FDA-approved prescription drug, marketed as Mounjaro (approved 2022 for type 2 diabetes) and Zepbound (approved 2023 for chronic weight management and, subsequently, for moderate-to-severe obstructive sleep apnea in adults with obesity).
Its evidence base is genuinely strong and built on large, double-blind, phase-3 randomized trials. In the SURPASS diabetes program, tirzepatide lowered HbA1c by roughly 1.9-2.6 percentage points and outperformed placebo, titrated basal insulin (degludec and glargine), and — head-to-head in SURPASS-2 — semaglutide 1 mg.
In the SURMOUNT obesity program, SURMOUNT-1 produced mean weight reductions of -15.0%, -19.5%, and -20.9% at 5, 10, and 15 mg over 72 weeks (vs -3.1% placebo), among the largest ever seen with a pharmacotherapy; SURMOUNT-5 then showed superiority over maximally-dosed semaglutide (-20.2% vs -13.7%).
SURMOUNT-OSA showed large reductions in the apnea-hypopnea index in obese adults with obstructive sleep apnea. This is not a supplement and should never be framed as one.
The most frequent adverse effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), mostly during dose escalation; it carries a boxed warning for thyroid C-cell tumors (contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2), plus signals for pancreatitis and gallbladder disease, and a portion of the weight lost is lean mass.
The FDA has repeatedly warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose. It is appropriate only under medical supervision for an approved indication.
Tirzepatide is a single peptide that simultaneously activates the GIP and GLP-1 receptors — the basis for its 'dual incretin' or 'twincretin' classification — producing additive effects on glucose handling and appetite.
Enhances glucose-dependent insulin release and improves insulin sensitivity, lowering HbA1c and fasting glucose without the hypoglycemia risk seen with insulin or sulfonylureas.
Acts on central appetite circuits and slows gastric emptying, reducing food intake — the primary driver of the large weight loss seen in the SURMOUNT trials.
How Tirzepatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
Can be taken without food
| Form | Type |
|---|---|
| 💊Once-weekly subcutaneous injection (Mounjaro / Zepbound) | Recommended |
| 💊Semaglutide (selective GLP-1 agonist; less weight loss head-to-head in SURPASS-2 and SURMOUNT-5) | Alternative |
Only the FDA-approved branded products have verified identity, purity, and dose. Do not use compounded or grey-market preparations.
Compare Tirzepatide vs Semaglutide →Minimum: 20 weeks
Optimal: 72 weeks
Cycling: Not required
Note: Once-weekly, same day each week, with or without food. Dose is escalated slowly (every 4 weeks) to limit GI side effects.
Dose-response data unavailable. The current published research for Tirzepatide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers HbA1c by roughly 1.9-2.6 percentage points in phase-3 diabetes trials; superior to placebo, basal insulin, and semaglutide 1 mg head-to-head.
Mean weight reductions up to ~21% over 72 weeks in obesity trials — the largest of any approved weight-loss drug to date, and superior to semaglutide head-to-head.
Reduced the apnea-hypopnea index by ~20-24 events/hour more than placebo in obese adults with moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA).
Nausea, diarrhea, vomiting, and constipation are common, mostly mild-to-moderate and concentrated during dose escalation.
A portion of the weight lost is lean (muscle) mass — a consideration with all GLP-1-based weight loss.
Contraindicated — boxed warning for thyroid C-cell tumors.
Use with caution or avoid; monitor for pancreatitis symptoms.
Contraindicated — discontinue before a planned pregnancy.
Hypoglycemia risk — concomitant doses usually need reduction under medical supervision.
Slowed gastric emptying may reduce the efficacy of oral contraceptives — a non-oral or backup contraceptive method is advised when starting and after each dose escalation.
Additive glucose-lowering raises hypoglycemia risk; doses of insulin/sulfonylureas often need reduction.
Tip: Slow dose escalation; smaller meals; usually subsides after titration
Tip: Hydration; slower escalation
Tip: Slower escalation; dietary adjustment
Tip: Fiber, fluids, activity
Tip: Expected effect; ensure adequate protein intake to limit lean-mass loss
Timing is flexible for Tirzepatide — consistent daily use matters more than the time of day. Administered once weekly, with or without food, on the same day each week.
Tirzepatide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, diarrhea, vomiting. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC); Multiple endocrine neoplasia syndrome type 2 (MEN2); History of pancreatitis (use with caution / avoid).
Liraglutide
Mostly mechanism / observationalAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.
Delayed gastric emptying can alter the absorption of co-administered oral drugs; clinically significant mainly for narrow-therapeutic-index agents.
Tip: Stop and seek care for severe persistent abdominal pain; avoid in those with a pancreatitis history
Tip: Seek care for right-upper-quadrant pain, fever, or jaundice